CompletedNCT00953862
Atomoxetine for people with ADHD in residential substance-use treatment
About this title
Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility
Read the official source — NCT00953862This study evaluated the effectiveness of Atomoxetine for people with ADHD.
Medication studyAges 18–60
Understand this study
What did researchers investigate?
This study evaluated the effectiveness of Atomoxetine for people with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
Study information
Study start dateJuly 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 18
- Sponsor
- NYU Langone Health
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- Not clearly listed
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT00953862
- Official title
Show the full official title
Efficacy of Atomoxetine in Adults With ADHD and Substance Abuse Disorder Being Treated in a Residential Treatment Facility
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Locations not listed
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the effectiveness of Atomoxetine for people with ADHD.
Who is behind this study?
The study sponsor is NYU Langone Health.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
